Surgepays, Inc. current report, 08 March 2021

Business Context and Reporting Period

This Form 8-K Current Report was filed by SurgePays, Inc. on March 16, 2021, covering events occurring on March 8, 2021. The filing details the entry into a material definitive agreement involving a private placement of debt and equity-linked securities.

Key Financial Metrics and Transaction Details

  • Proceeds Raised: $2,000,000 in cash proceeds.
  • Debt Instrument: 15% OID Convertible Promissory Note with a principal amount of $2,300,000.
  • Interest Rate: 5% per annum.
  • Maturity Date: March 8, 2022.
  • Conversion Price: $0.16 per share (subject to a 75% discount to VWAP upon an Event of Default).
  • Warrant Details: Warrant to purchase up to 13,437,500 shares of common stock at $0.16 per share, exercisable until March 8, 2026.
  • Transaction Costs: 8% cash fee to placement agent (Maxim Group, LLC) plus up to $20,000 in legal fee reimbursement.

Material Changes and Terms

The company entered into a Securities Purchase Agreement with Evergreen Capital Management LLC. Key terms include:

  • Prepayment Rights: The company may prepay the note at 115% of the outstanding balance before October 8, 2021, or 120% thereafter.
  • Qualified Financing: Mandatory prepayment is required upon the occurrence of a Qualified Financing.
  • Future Transactions: The investor may elect to apply the note principal and accrued interest as purchase consideration for any single Future Transaction.
  • Ownership Caps: Warrant exercise is limited if the investor would beneficially own more than 4.99% (or 9.99% under no circumstances) of outstanding shares post-exercise.

Outlook, Risks, and Contingencies

The filing does not provide specific forward-looking guidance, revenue projections, or management commentary regarding future operational performance. However, the following risks and contingencies are noted:

  • Dilution Risk: Significant potential dilution exists due to the low conversion price ($0.16) and the large number of warrant shares (13,437,500).
  • Liquidity Contingency: The company is obligated to prepay the note upon a Qualified Financing, which could impact future capital raising strategies.
  • Placement Agent Rights: The company granted Maxim Group, LLC a right of first refusal for future equity or debt offerings for 18 months.
  • Registration Status: The securities were issued under Section 4(a)(2) and Rule 506 of Regulation D and are not registered under the Securities Act of 1933.

Investor Verification Checklist

  • Verify the current market price of SurgePays common stock relative to the $0.16 conversion and warrant exercise price.
  • Confirm the company's current cash position and ability to service the 5% interest or prepay the note if a Qualified Financing occurs.
  • Review the definition of "Qualified Financing" and "Future Transaction" in the attached Securities Purchase Agreement to understand prepayment triggers.
  • Assess the potential dilution impact of the 13,437,500 warrant shares on existing shareholders.
  • Check for any subsequent filings regarding the registration of the warrant shares, as cashless exercise is permitted if shares are not registered after six months.